No Data
No Data
Beijing Centergate Technologies: 2024 Interim Performance Forecast
Zhongguancun (000931.SZ): Subsidiary company Duoduo Pharmaceutical Ambroxol Hydrochloride Injection received the “Notice of Acceptance” from the State Drug Administration
Gelonghui, April 29丨Zhongguancun (000931.SZ) announced that Duoduo Pharmaceutical Co., Ltd. (hereinafter: Duoduo Pharmaceutical), a subsidiary of the company, recently received the “Notice of Acceptance” of the registration application for the chemical generic drug ambroxol hydrochloride injection issued by the China Drug Administration (hereinafter referred to as the State Drug Administration).
Zhongguancun (000931.SZ): Net profit of 116.311 million yuan in the first quarter increased 22.88% year-on-year
Gelonghui, April 26 | Zhongguancun (000931.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 606 million yuan, up 3.06% year on year; net profit attributable to shareholders of listed companies was 116.311 million yuan, up 22.88% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 6.6067 million yuan, down 1.66% year on year; basic earnings per share were 0.0154 yuan.
Zhongguancun (000931.SZ): Subsidiary company Beijing Huasubanbazol API approved for listing
Gelonghui, April 22丨Zhongguancun (000931.SZ) announced that Beijing Huasu Pharmaceutical Co., Ltd. (hereinafter: Beijing Huasu), a subsidiary of Beijing Zhongguancun Science and Technology Development (Holdings) Co., Ltd. (hereinafter referred to as the Company), recently passed the technical review by the Drug Evaluation Center of the State Drug Administration (CDE) and obtained the “Notice of Approval of the Application for the Marketing of Chemical Ingredients” issued by the China Drug Administration (hereinafter referred to as the State Drug Administration). Bifonazole raw materials are indicated for antifungal infections. Bifonazol (Bifonaz
Zhongguancun (000931.SZ): Shandong huasuglipizide dispersible tablets are considered to have passed the consistency evaluation
Zhitong Finance App News, Zhongguancun (000931.SZ) issued an announcement. Recently, Shandong Huasu Pharmaceutical Co., Ltd. (hereinafter referred to as Shandong Huasu), a subsidiary of the company, received the “Drug Supplement Application Approval Notice” (Notice Number: 2024B01608) approved and issued by the State Drug Administration and learned that “glipyrazine dispersible tablets” (registered trademark: Yuantan) (specification: 5mg) produced by Shandong Huasu are treated as having passed the consistent evaluation of the quality and efficacy of generic drugs. Glipizide dispersible tablets (specification: 5mg) are second-generation sulfonylureas oral hypoglycemic agents. Oral absorption is rapid and complete, and half-life
Zhongguancun (000931.SZ): Subsidiary companies received the “Notice of Acceptance” from the State Drug Administration for the consistency evaluation of Beijing Huasu naloxone hydrochloride injection and the Shandong Huasu metoprolol succinate API applicat
Gelonghui, April 3, 丨 Zhongguancun (000931.SZ) announced that recently, Beijing Huasu Pharmaceutical Co., Ltd. (hereinafter: Beijing Huasu), the holding subsidiary of Beijing Zhongguancun Sihuan Pharmaceutical Development Co., Ltd., a wholly-owned subsidiary of the company, and Shandong Huasu Pharmaceutical Co., Ltd. (hereinafter: Shandong Huasu) received the “Notice of Acceptance” issued by the China Drug Administration (hereinafter referred to as the State Drug Administration), naloxone hydrochloride injection (specifications: 1ml: 0.4 mg, 1ml: 1mg, 2ml) Application for sexual evaluation Acceptance and metformin succinate
No Data